eClinical Technology and Industy News

Second Genome Presents Preclinical Data at Crohn’s & Colitis Foundation’s® IBD Innovate Conference for Potential First in Class Mucosal Healing Therapeutic SG-5-00455

SG-5-00455 delivered directly to the gut via engineered L. lactis system restores barrier function and improves mucosal healing in an ulcerative colitis model

Company also participates as new Crohn’s & Colitis Foundation Corporate Circle member to support Foundation’s IBD treatment, awareness and patient engagement initiatives

Excerpt from the Press Release:

BRISBANE, Calif. – November 18, 2021 – Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers, presented preclinical data from its mucosal healing program in inflammatory bowel disease (IBD) at the Crohn’s & Colitis Foundation’s IBD Innovate: Product Development in Crohn’s & Colitis® virtual conference held November 18-19, and announced its Corporate Circle membership for a three-year term.

SG-5-00455, the Company’s lead drug candidate from its drug and biomarker development program in IBD, could potentially be a first in class therapeutic that improves mucosal healing in IBD patients. SG-2-0776, a novel protein, was engineered into an L. lactis drug delivery system, SG-5-00455, for direct, non-systemic delivery to the gut. Mucosal healing is a key therapeutic goal for IBD and currently ranked by physicians as the top unmet need.*

“While it is known that the microbiome affects the gut immune system and mucosal health, the relationship between discrete microbial strains, secreted proteins and mucosal healing remains poorly understood. Our preclinical findings show bacteria associated with healthy human microbiota that are reduced in ulcerative colitis patients play an important role in gut homeostasis by producing proteins that display a novel mechanism of action related to extracellular matrix (ECM) binding, improved barrier function and mucosal healing in response to epithelial damage,” said Karim Dabbagh, Ph.D., Chief Executive Officer at Second Genome. “We are also proud to announce our Corporate Circle membership to the Crohn’s & Colitis Foundation. Patients urgently need new therapeutic approaches that improve their quality of life, and the Foundation is leading meaningful therapeutic discovery, disease awareness and patient assistance efforts leading to much needed innovation.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives